Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial
Authors:
Open Access
- 8 April 2026
- journal article
- research article
- Published by Springer Nature in Ophthalmic and Physiological Optics
- Vol. 46 (3) , 626-634
Abstract
Introduction: Stage 2 of the Childhood Atropine for Myopia Progression (CHAMP) study was conducted to observe the safety, efficacy and rebound effects of low-dose atropine sulphate ophthalmic solutions (0.01% and 0.02%) for paediatric myopia in the year following cessation of 3 years of prior treatment. Methods: The study was a multicentre, randomised, double-masked, placebo-controlled Phase 3 clinical trial. Children aged 3 to < 17 years with myopia (spherical equivalent refractive error (SER) from −0.50 to −6.00 D) who entered and completed Stage 1 (3 years of treatment) participated in the fourth-year follow-up (Stage 2). Stage 1 participants who were treated with atropine 0.01% or 0.02% were re-randomised 1:1:1 to atropine 0.01%, atropine 0.02% or vehicle in Stage 2. Stage 1 vehicle-treated participants were re-randomised 1:1 to atropine 0.01% or atropine 0.02% in Stage 2. Outcomes included changes in cycloplegic SER, changes in axial length (AL), responder status continuity and progression to high myopia. Results: Four hundred and twenty participants were randomised in Stage 2. Negligible rebound was observed among the participants who switched from 0.01% atropine to vehicle compared to those who continued on 0.01% atropine treatment (least square mean difference in SER change from Month 36 to Month 48 between continued treatment and switching to vehicle = 0.019 D, 95% CI [−0.14, 0.18], p = 0.82 for the modified Intent to Treat set). Stage 1 responders remained responders in 83-90% of participants in various Stage 2 groups. Safety profiles were favourable, with mild, transient adverse events. Conclusions: Atropine sulphate ophthalmic solution (0.01%) exhibited negligible rebound in myopia progression after treatment cessation following 3 years of continued treatment, highlighting its potential as a treatment option. The treatment maintained a favourable safety record, and the overall benefit and risk assessment support its potential use as a long-term myopia management option. Clinical trial registration: The Childhood Atropine for Myopia Progression (CHAMP) study was registered in clinicaltrials.gov (NCT03350620, registration date November 17, 2017).Keywords
Funding Information
- Vyluma, Inc.
This publication has 29 references indexed in Scilit:
- Efficacy and Safety of Different Atropine Regimens for the Treatment of Myopia in ChildrenJAMA Ophthalmology, 2025
- Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 YearsJAMA Ophthalmology, 2023
- Assessment of myopic rebound effect after discontinuation of treatment with 0.01% atropine eye drops in Japanese school-age childrenJapanese Journal of Ophthalmology, 2023
- Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia ControlJAMA Ophthalmology, 2023
- Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled studyJapanese Journal of Ophthalmology, 2021
- Low-Concentration Atropine for Myopia Progression (LAMP) StudyOphthalmology, 2019
- Association of Axial Length With Risk of Uncorrectable Visual Impairment for Europeans With MyopiaJAMA Ophthalmology, 2016
- Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050Ophthalmology, 2016
- Atropine for the Treatment of Childhood Myopia: Changes after Stopping Atropine 0.01%, 0.1% and 0.5%American Journal of Ophthalmology, 2014
- Atropine for the Treatment of Childhood Myopia: Effect on Myopia Progression after Cessation of AtropineOphthalmology, 2009